Last reviewed · How we verify
DOBUTAMINE HYDROCHLORIDE
At a glance
| Generic name | DOBUTAMINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Inotropic support in cardiac decompensation
Common side effects
- Nausea
- Headache
- Anginal pain
- Nonspecific chest pain
- Palpitations
- Shortness of breath
Key clinical trials
- Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock (NA)
- Artificial Intelligence Stress Echo (FINESSE) Project
- Impact Of Using LevosemidanVersus DobutamineOn Right Ventricular Function In AdultPatients Undergoing Elective Valve Replacement Surgery
- The PROTECT-HIE Trial (PHASE2)
- Cerebral Oxygen Saturation Monitoring In Cardiac Surgery (COSMICS) (NA)
- Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study (NA)
- Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
- Comparison Bewteen Intraoperative HPI vs. High Mean Arterial Pressure Threshold (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOBUTAMINE HYDROCHLORIDE CI brief — competitive landscape report
- DOBUTAMINE HYDROCHLORIDE updates RSS · CI watch RSS